Literature DB >> 31054837

Association of non-alcoholic fatty liver disease with microvascular complications of type 2 diabetes.

Mohsen Afarideh1, Zahra Aryan2, Alireza Ghajar3, Morsaleh Ganji3, Fatemeh Ghaemi4, Mohammad Saadat1, Behnam Heidari3, Jeffrey I Mechanick5, Alireza Esteghamati6.   

Abstract

INTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) affects risks of type 2 diabetes (T2D), diabetes-related complications, and cardiovascular disease in a complex manner. This study is designed to clarify associations of sonographically-detected NAFLD and serum liver enzymes with diabetes-related microvascular complications.
METHODS: A matched case-contorl study was designed for 440 patients with T2D and at least one of the chronic diabetes-related microvascular complications and 495 age- and gender-matched control patients with T2D.
RESULTS: Considering pre-existing and newly developed chronic microvascular complications, diabetic peripheral neuropathy was found in 347 out of 935 (37.1%) study patients, diabetic retinopathy in 141/935 (15.1%), and diabetic nephropathy in 103/935 (11.0%). Diagnosis of diabetic retinopathy and diabetic nephropathy were inversely associated with the presence of NAFLD in the crude logistic regressions (OR [95% CI] = 0.18 [0.05-0.63], p value = 0.007; OR [95% CI] = 0.17 [0.04-0.59], p value = 0.011, respectively). The subgroup of NAFLD with elevated liver enzymes had lower odds of having diabetic peripheral neuropathy in the fully adjusted model (OR [95% CI] = 0.34 [0.12-0.98], p value = 0.048).
CONCLUSION: Diagnosis of NAFLD with or without elevated serum liver enzymes was inversely correlated with certain chronic diabetes microvascular complications. Possible explanations for this counter-intuitive and unexpected finding are discussed and center on reverse-causality, wherein sicker patients may develop beneficial compensatory physiological and behavioral adaptations. Diversity of studied patients, in particular with regards to the ethnic and racial differences among the Western and Asian populations may also partly account for contrasting findings of the relationship between NAFLD and microvascular complications of diabetes.
Copyright © 2019 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chronic microvascular complications, type 2 diabetes; Non-alcoholic fatty liver disease

Mesh:

Substances:

Year:  2019        PMID: 31054837     DOI: 10.1016/j.pcd.2019.03.009

Source DB:  PubMed          Journal:  Prim Care Diabetes        ISSN: 1878-0210            Impact factor:   2.459


  5 in total

1.  Association Between the Risk of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease.

Authors:  Pingping Zhao; Junxin Yan; Binjing Pan; Jingfang Liu; Songbo Fu; Jianguo Cheng; Liting Wang; Gaojing Jing; Qiong Li
Journal:  Diabetes Metab Syndr Obes       Date:  2022-04-14       Impact factor: 3.249

Review 2.  Beyond the Liver: Liver-Eye Communication in Clinical and Experimental Aspects.

Authors:  Tian-Hao Yuan; Zhen-Sheng Yue; Guo-Heng Zhang; Lin Wang; Guo-Rui Dou
Journal:  Front Mol Biosci       Date:  2021-12-24

Review 3.  Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota.

Authors:  Karolina Drożdż; Katarzyna Nabrdalik; Weronika Hajzler; Hanna Kwiendacz; Janusz Gumprecht; Gregory Y H Lip
Journal:  Nutrients       Date:  2021-12-27       Impact factor: 5.717

4.  Clinico-pathological features and related risk factors of Type-2 diabetes mellitus complicated with nonalcoholic fatty liver.

Authors:  Lisha Chen; Li Jiang
Journal:  Pak J Med Sci       Date:  2022 Sep-Oct       Impact factor: 2.340

5.  Association of non-alcoholic fatty liver disease with diabetic retinopathy in type 2 diabetic patients: A meta-analysis of observational studies.

Authors:  Dandan Song; Chengqian Li; Zhongchao Wang; Yuhang Zhao; Baoming Shen; Wenjuan Zhao
Journal:  J Diabetes Investig       Date:  2021-02-01       Impact factor: 4.232

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.